Ashley Love Sumrall: Why Neuro-Oncology?
Ashley Love Sumrall, Neuro-Oncologist, Medical Oncologist, Hematologist, Associate Professor, and Section Chief of Neuro-Oncology, Levine Cancer Institute, at Atrium Health, shared a post on X:
” ‘Why neuro-oncology?’ they ask.
‘It’s so depressing.’
‘You don’t have much chemo.’ ‘It’s hard.’
I disagree! This is part of my why… although I can’t show you this screen… yet!
Every neuro-onc (and oncologist) dreams of helping a drug make it to FDA approval. Approximately 8years ago, I begged our Levine Cancer Institute trials team to help me quickly open a promising trial for patients with a rare subtype of brain cancer. They blew me away… compressing months of work into weeks!
I met with a small team from Oncoceutics. We successfully opened 2 trials and treated people from around the world with ONC201, offering a therapy for a condition with ZERO approved options. We watched FDA consider the therapy over the years, only to be told to wait…
In June, I was thrilled to present updated data for dordaviprone for kids and adults with H3K27m glioma ASCO25.
What a JOY it was, on behalf of patients and families, to learn earlier this month that the FDA said YES! Modeyso (dordaviprone) or ONC201 is now available for kids and adults with H3K27m diffuse midline glioma DMG. It is an incredible honor to contribute in a small way to this!
I am so grateful to our brave patients and families who continue to teach us every day. Today, I joined Dr Yazmin Odia and my friends from Chimerix, Jazz Pharmaceuticals to celebrate the launch of Modeyso. May the future shine brighter for our current and future patients!”
More posts featuring Ashley Love Sumrall.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023